Tags

Type your tag names separated by a space and hit enter

Lipid disturbances in psoriasis: an update.

Abstract

Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Dermatology, Venereology and Paediatric Dermatology, Medical University of Lublin, ul. Radziwillowska 13, 20-080 Lublin, Poland.

    , ,

    Source

    MeSH

    Apolipoproteins
    Cholesterol
    Humans
    Lipid Metabolism
    Lipids
    Oxidative Stress
    Psoriasis
    Skin

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    20706605

    Citation

    Pietrzak, Aldona, et al. "Lipid Disturbances in Psoriasis: an Update." Mediators of Inflammation, vol. 2010, 2010.
    Pietrzak A, Michalak-Stoma A, Chodorowska G, et al. Lipid disturbances in psoriasis: an update. Mediators Inflamm. 2010;2010.
    Pietrzak, A., Michalak-Stoma, A., Chodorowska, G., & Szepietowski, J. C. (2010). Lipid disturbances in psoriasis: an update. Mediators of Inflammation, 2010, doi:10.1155/2010/535612.
    Pietrzak A, et al. Lipid Disturbances in Psoriasis: an Update. Mediators Inflamm. 2010;2010 PubMed PMID: 20706605.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Lipid disturbances in psoriasis: an update. AU - Pietrzak,Aldona, AU - Michalak-Stoma,Anna, AU - Chodorowska,Grazyna, AU - Szepietowski,Jacek C, Y1 - 2010/07/20/ PY - 2010/04/12/received PY - 2010/06/10/accepted PY - 2010/8/14/entrez PY - 2010/8/14/pubmed PY - 2010/12/14/medline JF - Mediators of inflammation JO - Mediators Inflamm. VL - 2010 N2 - Psoriasis is a common disease with the population prevalence ranging from 2% to 3%. Its prevalence in the population is affected by genetic, environmental, viral, infectious, immunological, biochemical, endocrinological, and psychological factors, as well as alcohol and drug abuse. In the recent years, psoriasis has been recognised as a systemic disease associated with numerous multiorgan abnormalities and complications. Dyslipidemia is one of comorbidities in psoriatic patients. Lipid metabolism studies in psoriasis have been started at the beginning of the 20th century and are concentrated on skin surface lipids, stratum corneum lipids and epidermal phospholipids, serum lipids, dermal low-density lipoproteins in the psoriatic skin, lipid metabolism, oxidative stress and correlations between inflammatory parameters, lipid parameters and clinical symptoms of the disease. On the basis of the literature data, psoriasis can be described as an immunometabolic disease. SN - 1466-1861 UR - https://www.unboundmedicine.com/medline/citation/20706605/full_citation L2 - https://dx.doi.org/10.1155/2010/535612 DB - PRIME DP - Unbound Medicine ER -